PHASE II STUDY OF IODINE 131 ANTI BI ANTIBODY FOR NON HODGKINS LYMPHOMA

碘131抗双抗体治疗非霍奇金淋巴瘤的II期研究

• 批准号: 6305118
• 负责人: SANDRA J. HORNING
• 金额: $ 0.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6305118
• 关键词: antibody; clinical research; dosage; drug screening /evaluation; human subject; human therapy evaluation; iodine; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; nonHodgkin's lymphoma; radionuclides

Both radioimmunotherapy and the unlabeled monoclonal antibody, rituximab, have clinical activity in low-grade lymphomas. Theoretically, patients who have been previously treated with rituximab may mount an immune response that would preclude subsequent uses of other antibody treatments. This study is being performed to determine the activity and safety of Iodine-131 Anti-B1 Antibody therapy in patients who have been previously treated with the anti-CD20 monoclonal antibody, rituximab.

放射免疫疗法和未标记的单抗利妥昔单抗对低度恶性淋巴瘤均有临床活性。从理论上讲，以前接受过利妥昔单抗治疗的患者可能会产生免疫反应，从而排除随后使用其他抗体治疗的可能性。这项研究是为了确定碘-131抗B1抗体治疗患者的活性和安全性，这些患者以前曾接受过抗CD20单抗利妥昔单抗治疗。